LYEL — Lyell Immunopharma
Median target
$34
calls from the last 12 months
Implied return
+214.8%
median target vs. price
Coverage
5 analysts · 5 calls
updated in the last 12 months
Consensus
4/0/1+3 net
Buy / Hold / Sell
Which analysts are behind LYEL's consensus?
See every current rating, price target and the analysts' track records for Lyell Immunopharma — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 5 analysts with calls on LYEL updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
LYEL elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-09-10 | Insiders | Shook DavidChief Medical Officer | Insider sale | 500 sh @ $12.70 | $6K |
| 2026-08-21 | Insiders | Seely LynnPresident and CEO | Insider sale | 9.6K sh @ $15.54 | $149K |
| 2026-08-21 | Insiders | Lee Gary K.Chief Scientific Officer | Insider sale | 1.5K sh @ $15.54 | $23K |
| 2026-08-21 | Insiders | Hill Stephen J.Chief Operating Officer | Insider sale | 989 sh @ $15.54 | $15K |
| 2026-08-10 | Insiders | Bulis Veronica SanchezVP, Corporate Controller | Insider sale | 621 sh @ $14.34 | $9K |
| 2026-08-10 | Insiders | Seely LynnPresident and CEO | Insider sale | 390 sh @ $14.34 | $6K |
| 2026-08-10 | Insiders | Lee Gary K.Chief Scientific Officer | Insider sale | 131 sh @ $14.34 | $2K |
| 2026-08-10 | Insiders | Hill Stephen J.Chief Operating Officer | Insider sale | 89 sh @ $14.34 | $1K |
More: insider activity · executive branch · trending